-
European Drug Regulator EMA Suspends Use Of MRI Drugs Magnevist, Omniscan, And OptiMARK In July 2017
The Drug Safety Concern Is That Use Of These Gadolinium Contrast Agents Can Leave Gadolinium Deposits In Brain Tissues (Posted by Tom Lamb at DrugInjuryWatch.com) The European Medicines Agency (EMA) recently announced…
-
Invokana – Amputation Side Effect Gets “Black-Box Warning” On Revised Drug Label Issued In July 2017
This Label Change Was Previewed In A May 2017 FDA Drug Safety Communication About Increased Risk Of Leg And Foot Amputations (Posted by Tom Lamb at DrugInjuryWatch.com) A June 2017 article, “Invokana…
-
Keytruda, Opdivo, And Yervoy May Be Associated With Vision Loss And Retinal Detachment In Addition To Uveitis
In June 2017 The FDA Announced It Is Evaluating Possible Drug Label Changes And The Need For Other Regulatory Actions (Posted by Tom Lamb at DrugInjuryWatch.com) According to the document “Potential Signals…
-
Despite The High Number Of Actemra – Pancreatitis Cases Reported To FDA, No Warning Added To Drug Label
June 2017 Investigative Article Published By STAT Calls Into Question FDA Oversight After Drugs Are Approved By Agency (Posted by Tom Lamb at DrugInjuryWatch.com) Actemra (tocilizumab) is approved by the FDA for…
-
There Is Continuing Concern About Whether Victoza Is Associated With Pancreatic Cancer As A Possible Side Effect
The FDA Briefing Materials For A June 2017 Advisory Committee Meeting On Victoza Include A Discussion Of This Safety Issue (Posted by Tom Lamb at DrugInjuryWatch.com) On June 20, 2017 there will…
-
Jardiance, Invokana, Farxiga, And The Other SGLT2 Inhibitors Might Double The Risk Of Diabetic Ketoacidosis (DKA)
Study Compared Newly Initiated Use Of SGLT2 Inhibitor To New Initiation Of Another Class Of Diabetes Drugs To Assess The DKA Side Effect (Posted by Tom Lamb at DrugInjuryWatch.com) All of these…
